Ginkgo Bioworks Holdings, Inc. (DNA)
$
12.92
-1.04 (-8.05%)
Key metrics
Financial statements
Free cash flow per share
-6.3660
Market cap
817.1 Million
Price to sales ratio
3.4416
Debt to equity
0.6712
Current ratio
4.8807
Income quality
0.5970
Average inventory
0
ROE
-0.6306
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$559,757,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.83 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $188,494,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -2.47 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $9.94 catering to budget-conscious investors. With a high average trading volume of 1,420,434.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $756,231,812.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Is Ginkgo Bioworks Holdings, Inc. (DNA) a good investment?
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Ginkgo Bioworks Holdings, Inc. (DNA)'s stock forecast?
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $16.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ginkgo Bioworks Holdings, Inc.'s market capitalization?
As of 2025-07-29, Ginkgo Bioworks Holdings, Inc.'s market cap is $756,231,812, based on 58,531,874 outstanding shares.
How does Ginkgo Bioworks Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ginkgo Bioworks Holdings, Inc. (DNA) stock?
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ginkgo Bioworks Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ginkgo Bioworks Holdings, Inc. stock ever split?
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
How did Ginkgo Bioworks Holdings, Inc. perform in the last earnings report?
Revenue: $227,043,000 | EPS: -$10.54 | Growth: -42.62%.
Where can I find Ginkgo Bioworks Holdings, Inc.'s investor relations reports?
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ginkgo Bioworks Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Ginkgo Bioworks Holdings, Inc. stock?
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
What are the key trends affecting Ginkgo Bioworks Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $13.96, signifying a -6.31% move from its prior day's close.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.6, signifying a +1.8% move from its prior day's close.
zacks.com
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $10.79, denoting a -2.53% move from the preceding trading day.
benzinga.com
Meta Platforms, Inc. META CEO Mark Zuckerberg has made a decisive move to reshape the company's entire AI strategy by consolidating all artificial intelligence efforts under a newly formed division called Meta Superintelligence Labs.
accessnewswire.com
Division of Silver Scott Mines, Inc. Expands Health and Wellness Offerings FRANKLIN, NJ / ACCESS Newswire / June 24, 2025 / Silver Scott Health, Inc., a division of Silver Scott Mines, Inc. (OTC PINK:SILS), today announced a distribution agreement with DNA Vibe, the innovator behind patented red light therapy devices. Beginning in the third quarter, DNA Vibe's wearable wellness technology will be available for purchase on the Silver Scott Health website, furthering the company's mission to bring scientifically-backed, non-invasive health and wellness solutions to consumers.
accessnewswire.com
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term.
nypost.com
23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of millions of customers.
reuters.com
Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron's bid for the DNA-testing company.
prnewswire.com
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
accessnewswire.com
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C.
See all news
